{"nctId":"NCT04435600","briefTitle":"A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms","startDateStruct":{"date":"2020-07-14","type":"ACTUAL"},"conditions":["Psoriasis"],"count":139,"armGroups":[{"label":"Part 1: Risankizumab Dose A","type":"EXPERIMENTAL","interventionNames":["Drug: Risankizumab"]},{"label":"Part 2: Ustekinumab Dose A/B/C then Risankizumab Dose A/B","type":"EXPERIMENTAL","interventionNames":["Drug: Risankizumab","Drug: Ustekinumab"]},{"label":"Part 2: Risankizumab Dose A/B","type":"EXPERIMENTAL","interventionNames":["Drug: Risankizumab"]},{"label":"Part 3: Risankizumab Dose A/B","type":"EXPERIMENTAL","interventionNames":["Drug: Risankizumab"]},{"label":"Part 4: Risankizumab Dose A/B","type":"EXPERIMENTAL","interventionNames":["Drug: Risankizumab"]}],"interventions":[{"name":"Risankizumab","otherNames":["SKYRIZI","ABBV-066"]},{"name":"Ustekinumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of chronic plaque psoriasis for at least 6 months before the Baseline Visit.\n* Stable severe or moderate to severe plaque psoriasis as defined in each study part by body surface area (BSA) psoriasis involvement and scores on the Psoriasis Area and Severity Index (PASI) and Static Physician Global Assessment (sPGA).\n* Candidate for systemic therapy as assessed by the investigator and meet the disease activity criteria at both the Screening and Baseline Visits per the protocol.\n\nExclusion Criteria:\n\n\\- Concurrent clinically significant medical conditions other than the indication being studied or any other reason that the investigator determines would interfere with the participant's participation in this study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk by participating in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI)","description":"The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 75% improvement in PASI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"85.7","spread":null},{"groupId":"OG002","value":"85.2","spread":null},{"groupId":"OG003","value":"92.3","spread":null},{"groupId":"OG004","value":"86.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1)","description":"The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"75.0","spread":null},{"groupId":"OG002","value":"79.6","spread":null},{"groupId":"OG003","value":"84.6","spread":null},{"groupId":"OG004","value":"90.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline","description":"The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"67.9","spread":null},{"groupId":"OG002","value":"68.5","spread":null},{"groupId":"OG003","value":"84.6","spread":null},{"groupId":"OG004","value":"83.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)","description":"The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 90% improvement in PASI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"60.7","spread":null},{"groupId":"OG002","value":"64.8","spread":null},{"groupId":"OG003","value":"84.6","spread":null},{"groupId":"OG004","value":"76.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)","description":"The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 100% improvement in PASI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null},{"groupId":"OG001","value":"17.9","spread":null},{"groupId":"OG002","value":"40.7","spread":null},{"groupId":"OG003","value":"53.8","spread":null},{"groupId":"OG004","value":"43.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (0 or 1)","description":"The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline","description":"The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)","description":"The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 50% improvement in PASI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"92.9","spread":null},{"groupId":"OG002","value":"90.7","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"96.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)","description":"The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 50% improvement in PASI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)","description":"The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 90% improvement in PASI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)","description":"The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 100% improvement in PASI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI)","description":"The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 75% improvement in PASI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score","description":"The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL). The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item was scored on a 4-point scale: 0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":"0.66"},{"groupId":"OG001","value":"-7.4","spread":"0.49"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score","description":"The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL). The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item was scored on a 4-point scale: 0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"2.88"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score","description":"The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on Quality of Life (QOL) of family members. It consists of 10 questions that assess the impact of skin diseases on different aspects of the family member's QOL. Each item was scored on a 4-point scale: 0 = not at all; 1 = a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"0.84"},{"groupId":"OG001","value":"-6.9","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score","description":"The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on Quality of Life (QOL) of family members. It consists of 10 questions that assess the impact of skin diseases on different aspects of the family member's QOL. Each item was scored on a 4-point scale: 0 = not at all; 1 = a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"3.29"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Itch Numerical Rating Scale (Itch NRS)","description":"The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch. The itch NRS scale scores varies between 0, representing \"no itching\" and 10, representing \"worst itch imaginable\" with higher scores representing worse outcomes. A negative change from baseline indicates less intense itching and better outcomes.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"0.50"},{"groupId":"OG001","value":"-3.8","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Itch Numerical Rating Scale (Itch NRS)","description":"The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch. The itch NRS scale scores varies between 0, representing \"no itching\" and 10, representing \"worst itch imaginable\" with higher scores representing worse outcomes. A negative change from baseline indicates less intense itching and better outcomes.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"1.68"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving >= 4-point Improvement in the Itch Numerical Rating Scale (in Participants With Baseline Score >= 4)","description":"The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch within a 24-hour recall period. The itch NRS scale scores varies between 0, representing \"no itching\" and 10, representing \"worst itch imaginable\" with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving \\>= 4 point improvement in the itch NRS in participants with a baseline itch NRS score of \\>=4.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null},{"groupId":"OG001","value":"64.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["NASOPHARYNGITIS","HEADACHE","COVID-19","COUGH","PYREXIA"]}}}